XINT — Xintela AB Share News
0.000.00%
Last trade - 00:00- SEK200.68m
- SEK190.89m
- SEK2.28m
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects
Brief: Xintela Q4 Loss Before Tax Widens To SEK 17.3 Mln
Sweden's Xintela Q4 income drops 62% yr/yr
Brief: Xintela Completes Clinical Study With XSTEM In Difficult-To-Heal Leg Ulcers
Brief: Xintela Announces Rights Issue Of Up To SEK 72.8 Mln
Brief: Xintela Q3 Loss Before Tax Widens To SEK 10.4 Mln
Brief: Xintela: Targinta Collaborates With MSK For Antibody Development
Brief: Xintela Q2 Net Sales Up At SEK 872,000
Brief: Xintela Completes Clinical Study With Xstem In Knee Osteoarthritis
Brief: Xintela Q1 Pre-Tax Loss At SEK 10.4 Mln
Brief: Xintela, EQGen Biomedical Sign Collaboration And License Deal
Brief: Xintela Q4 Pre-Tax Loss Narrows To SEK 11.7 Mln
Brief: Xintela Q3 EPS at SEK -0.01
Brief: Xintela Q3 Loss Before Tax At SEK 8 Mln
Brief: Xintela's Flerie Undertakes To Exercise Warrants, Provides Bridge Loan
Brief: Xintela Signs Agreement Worth SEK 3.6 Mln